MKSAP 17 Audio Companion - Hematology

• MKSAP_17_Audio_Companion_Hematology.pdf
• 1-01 Introduction to Hematology Section.m4a
• 1-02 Hematopoietic Stem Cells and Their Disorders.m4a
• 1-03 Aplastic Anemia.m4a
• 1-04 Therapy.m4a
• 1-05 Question Break 1 A 43-year-old Woman is Admitted for Fatigue, Easy Bruising and Bleeding Gums.m4a
• 1-06 Pure Red Cell Aplasia.m4a
• 1-07 Isolated Neutropenia.m4a
• 1-08 Question Break 2 A 68-year-old Man is Evaluated for Dyspnea on Exertion.m4a
• 1-09 The Myelodysplastic Syndromes.m4a
• 1-10 International Prognostic Scoring System.m4a
• 1-11 Myeloproliferative Neoplasms.m4a
• 1-12 Chronic Myeloid Leukemia.m4a
• 1-13 Session 1 Key Points.m4a
• 1-14 Close to Session 1.m4a
• 2-01 Introduction to Session 2.m4a
• 2-02 The Philadelphia Chromosome.m4a
• 2-03 Medications.m4a
• 2-04 Polycythemia Vera.m4a
• 2-05 Causes of Secondary Erythrocytosis.m4a
• 2-06 Clinical Features and Diagnosis.m4a
• 2-07 Question Break 3 A 48-year-old Woman is Evaluated for Fatigue and Abdominal Discomfort.m4a
• 2-08 Essential Thrombocythemia.m4a
• 2-09 Presentation.m4a
• 2-10 Question Break 4 A 47-year-old Woman is Evaluated for Fatigue and Easy Bruising.m4a
• 2-11 Primary Myelofibrosis.m4a
• 2-12 Eosinophilia and Hypereosinophilic Syndromes.m4a
• 2-13 Session 2 Key Points.m4a
• 2-14 Close to Session 2.m4a
• 3-01 Introduction to Session 3.m4a
• 3-02 Acute Myeloblastic Leukemia.m4a
• 3-03 Therapy.m4a
• 3-04 Genetic Risk Profile and Effect on 5-year Survival in AML.m4a
• 3-05 Acute Promyelocytic Leukemia.m4a
• 3-06 Question Break 5 A 24-year-old is Seen for Dyspnea on Exertion and Severe Fatigue.m4a
• 3-07 Acute Lymphoblastic Leukemia.m4a
• 3-08 Hematopoietic Growth Factors.m4a
• 3-09 Hematopoietic Stem Cell Transplantation.m4a
• 3-10 Multiple Myeloma and Related Disorders.m4a
• 3-11 Evaluation for Monoclonal Gammopathies.m4a
• 3-12 Question Break 6 A 36-year-old Woman is Seen for Abdominal Pain, Swelling and Weight Gain.m4a
• 3-13 Monoclonal Gammopathy of Undetermined Significance.m4a
• 3-14 Risk of Progression to a Clinically Symptomatic Plasma Cell Dyscrasia.m4a
• 3-15 Multiple Myeloma.m4a
• 3-16 Diagnosis and Prognosis.m4a
• 3-17 Treatment.m4a
• 3-18 Session 3 Key Points.m4a
• 3-19 Close to Session 3.m4a
• 4-01 Introduction to Session 4.m4a
• 4-02 Immunoglobulin Light-Chain Amyloidosis.m4a
• 4-03 Diagnosis.m4a
• 4-04 Waldenstrom Macroglobulinemia.m4a
• 4-05 Cryoglobulinemia.m4a
• 4-06 Question Break 7 A 52-year-old Man is Seen for Orthopnea and Dyspnea on Exertion.m4a
• 4-07 Approach to Anemia.m4a
• 4-08 Iron Deficiency.m4a
• 4-09 Approach to Iron Replacement.m4a
• 4-10 Inflammatory Anemia.m4a
• 4-11 Anemia of Kidney Disease.m4a
• 4-12 Cobalamin Deficiency.m4a
• 4-13 Question Break 8 A 79-year-old Woman is Found to Have New-Onset Anemia.m4a
• 4-14 Folate Deficiency.m4a
• 4-15 Hemolytic Anemias.m4a
• 4-16 Hereditary Spherocytosis.m4a
• 4-17 Glucose-6-Phosphate Dehydrogenase Deficiency.m4a
• 4-18 Session 4 Key Points.m4a
• 4-19 Close to Session 4.m4a
• 5-01 Introduction to Session 5.m4a
• 5-02 Thalassemia.m4a
• 5-03 alpha-thalassemia.m4a
• 5-04 beta-thalassemia.m4a
• 5-05 Sickle Cell Syndromes.m4a
• 5-06 Sickle Cell Disease Complications and Their Management.m4a
• 5-07 Common Complications and Treatments in Adults with Sickle Cell Disease.m4a
• 5-08 Other Characteristics of SCD.m4a
• 5-09 Question Break 9 An 18-year-old Iron Deficient Woman is Seen for Follow-Up Evaluation.m4a
• 5-10 Erythrocyte Transfusions in Sickle Cell Disease.m4a
• 5-11 Other Hemoglobinopathies.m4a
• 5-12 Immune-Mediated Hemolysis.m4a
• 5-13 Warm Autoimmune Hemolytic Anemia.m4a
• 5-14 Cold Agglutinin Disease.m4a
• 5-15 Drug-Induced Immune Hemolytic Anemia.m4a
• 5-16 Non-Immune Hemolytic Anemia.m4a
• 5-17 Question Break 10 A 25-year-old Man is Seen for Brown Urine, Fatigue, and Shortness of Breath.m4a
• 5-18 Paroxysmal Nocturnal Hemoglobinuria.m4a
• 5-19 Macroangiopathic Hemolytic Anemia and March Hemoglobinuria.m4a
• 5-20 Hemolysis Associated with Chemical and Physical Agents.m4a
• 5-21 Iron Overload Syndromes.m4a
• 5-22 Secondary Iron Overload.m4a
• 5-23 Normal Platelet Physiology.m4a
• 5-24 Approach to the Patient with Thrombocytopenia.m4a
• 5-25 Session 5 Key Points.m4a
• 5-26 Close to Session 5.m4a
• 6-01 Introduction to Session 6.m4a
• 6-02 Thrombocytopenic Disorders.m4a
• 6-03 Non-Immune Mediated Thrombocytopenia.m4a
• 6-04 Hemolytic Uremic Syndrome.m4a
• 6-05 Immune-Mediated Thrombocytopenia.m4a
• 6-06 Immune Thrombocytopenic Purpura.m4a
• 6-07 Heparin-Induced Thrombocytopenia.m4a
• 6-08 Acquired Platelet Dysfunction.m4a
• 6-09 Platelet Function Testing.m4a
• 6-10 Question Break 11 A 30-year-old Woman is Seen with Symptoms of Fatigue.m4a
• 6-11 Normal Hemostasis.m4a
• 6-12 Evaluation of Patients with Suspected Bleeding Disorders.m4a
• 6-13 Question Break 12 A 19-year-old Woman is Seen for Weakness and Dyspnea During Exercise.m4a
• 6-14 Hemophilia A and B.m4a
• 6-15 Von Willebrand Disease.m4a
• 6-16 Coagulopathy of Liver Disease.m4a
• 6-17 Acquired Hemophilia.m4a
• 6-18 Disseminated Intravascular Coagulation.m4a
• 6-19 Session 6 Key Points.m4a
• 6-20 Close to Session 6.m4a
• 7-01 Introduction to Session 7.m4a
• 7-02 ABO Rh System and Compatibility Testing.m4a
• 7-03 Clinical Transfusion Issues.m4a
• 7-04 Strategies to Minimize Blood Transfusions.m4a
• 7-05 ABO Rh System, Human Leukocyte Antigen System, and Compatibility Testing.m4a
• 7-06 Clinical Transfusion Issues.m4a
• 7-07 Platelet Transfusion Refractoriness.m4a
• 7-08 Fresh Frozen Plasma.m4a
• 7-09 Cryoprecipitate and Other Plasma-Derived Transfusion Products.m4a
• 7-10 Acute and Delayed Hemolytic Transfusion Reactions.m4a
• 7-11 Transfusion-Associated Circulatory Overload.m4a
• 7-12 Transfusion-Related Acute Lung Injury.m4a
• 7-13 Febrile Nonhemolytic Transfusion Reaction.m4a
• 7-14 Allergic Reactions and Anaphylaxis.m4a
• 7-15 Transfusion-Associated Graft-versus-Host Disease.m4a
• 7-16 Infectious Complications.m4a
• 7-17 Therapeutic Apheresis.m4a
• 7-18 Pathophysiology of Thrombosis and Thrombophilia.m4a
• 7-19 Thrombophilia.m4a
• 7-20 Factor V Leiden.m4a
• 7-21 Prothrombin 20210A Gene Mutation.m4a
• 7-22 Antithrombin Deficiency.m4a
• 7-23 Session 7 Key Points.m4a
• 7-24 Close to Session 7.m4a
• 8-01 Introduction to Session 8.m4a
• 8-02 Protein C Deficiency and Protein S Deficiency.m4a
• 8-03 Other Inherited Thrombophilic Disorders.m4a
• 8-04 Acquired Thrombophilic Conditions.m4a
• 8-05 Cancer as a Risk for VTE.m4a
• 8-06 Antiphospholipid Antibody Syndrome.m4a
• 8-07 Diagnostic Criteria for Antiphospholipid Syndrome.m4a
• 8-08 Medications that Increase the Risk for VTE.m4a
• 8-09 Other Acquired Thrombophilic Conditions.m4a
• 8-10 Deep Venous Thrombosis and Pulmonary Embolism.m4a
• 8-11 Diagnosis.m4a
• 8-12 Treatment.m4a
• 8-13 Duration of Anticoagulant Therapy for VTE.m4a
• 8-14 Long-Term Complications.m4a
• 8-15 Superficial Thrombophlebitis.m4a
• 8-16 Upper Extremity DVT.m4a
• 8-17 Budd-Chiari Syndrome.m4a
• 8-18 Portal and Mesenteric Vein Thrombosis.m4a
• 8-19 Session 8 Key Points.m4a
• 8-20 Close to Session 8.m4a
• 9-01 Introduction to Session 9.m4a
• 9-02 Splenic Vein, Cerebral and Sinus Vein Thrombosis.m4a
• 9-03 Retinal Vein Thrombosis.m4a
• 9-04 Unexplained Arterial Thrombosis.m4a
• 9-05 Anticoagulants.m4a
• 9-06 Unfractionated and Low-Molecular-Weight Heparin.m4a
• 9-07 Fondaparinux.m4a
• 9-08 Warfarin.m4a
• 9-09 Management Strategy for Elevated INRs and Bleeding.m4a
• 9-10 New Oral Anticoagulants.m4a
• 9-11 Gestational Anemia and Sickle Cell Disease in Pregnancy.m4a
• 9-12 Thrombocytopenia in Pregnancy.m4a
• 9-13 Immune Thrombocytopenic Purpura.m4a
• 9-14 Microangiopathy of Pregnancy.m4a
• 9-15 Thrombophilia and Venous Thromboembolism in Pregnancy.m4a
• 9-16 Prevention and Diagnosis.m4a
• 9-17 Treatment.m4a
• 9-18 Session 9 Key Points.m4a
• 9-19 Close to Hematology Section.m4a